Dietary supplementation with n-3 polyunsaturated fatty acids attenuates the depression of food-motivated behavior during zymosan-induced peritonitis

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 7, 2005, Pages 1291-1293

  Takenaka, Mizuki ^a   Kanada, Satoko ^a   Hamazaki, Tomohito ^a   Watanabe, Shiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Mouse; N 3 polyunsaturated fatty acid (PUFA); Peritonitis; Prostaglandin; Sickness behavior; Zymosan

Indexed keywords

OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG MECHANISM; FEEDING BEHAVIOR; MALE; MOTIVATION; MOUSE; NONHUMAN; PERITONEUM; PERITONITIS; WRITHING TEST;

ANIMALS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEEDING BEHAVIOR; MICE; MOTIVATION; PERITONITIS; TRIGLYCERIDES; ZYMOSAN;

EID: 24944503942     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.28.1291     Document Type: Article

References (25)

1. Perry V. H., Brain Behav. Immun., 18, 407-413 (2004).
2. Dantzer R., Eur. J. Pharmacol., 500, 399-411 (2004).
3. Fishkin R. J., Winslow J. T., Psychopharmacology, 132, 335-341 (1997).
4. Bluthe R.-M., Lye S., Michaud B., Combe C., Dantzer R., Parnet P., Eur. J. Neurosci., 12, 4447-4456 (2000).
5. Bluthe R.-M., Michaud B., Poli V., Dantzer R., Physiol. Behav., 70, 367-373 (2000).
6. Swiergiel A. H., Dunn A. J., Brain Behav. Immun., 13, 252-265 (1999).
7. Swiergiel A. H., Dunn A. J., Pharmacol. Biochem. Behav., 69, 659-663 (2001).
8. Swiergiel A. H., Dunn A. J., J. Pharmacol. Exp. Ther., 302, 1031-1036 (2002).
9. Watanabe S., Kanada S., Takenaka M., Hamazaki T., Physiol. Behav., 81, 605-613 (2004).
10. Needleman P., Raz A., Minkes M. S., Ferrendelli J. A., Sprecher H., Proc. Natl. Acad. Sci. U.S.A., 76, 944-948 (1979).
11. Gryglewski R. J., Salmon J. A., Ubatuba F. B., Weatherly N. C., Moncada S., Vane J. R., Prostaglandins, 18, 453-478 (1979).
12. Watanabe S., Hayashi H., Onozaki K., Okuyama H., Life Sci., 48, 2013-2020 (1991).
13. Watanabe S., Katagiri K., Onozaki K., Hata N., Misawa Y., Hamazaki T., Okuyama H., Prostagl. Leukotr. Essent. Fatty Acids, 62, 147-152 (2000).
14. Doherty N. S., Beaver T. H., Chan K. Y., Dinerstein R. J., Diekema K. A., Br. J. Pharmacol., 101, 869-874 (1990).
15. Fujiyoshi T., Iida H., Kuwashima M., Dozen M., Taniguchi N., Ikeda K., J. Pharmacobio-Dyn., 13, 44-48 (1990).
16. Jose P. J., Forrest M. J., Williams T. J., Agents Actions, 16, 39-40 (1985).
17. Ueno A., Matsumoto H., Naraba H., Ikeda Y., Ushikubi F., Matsuoka T., Narumiya S., Sugimoto Y., Ichikawa A., Oh-ishi S., Biochem. Pharmacol., 62, 157-160 (2001).
18. Fantuzzi G., Sacco S., Ghezzi P., Dinarello C. A., Am. J. Physiol., 273, R400-406 (1997).
19. Cremeans-Smith J. K., Newberry B. H., Physiol. Behav., 80, 177-184 (2003).
20. Li B., Birdwell C., Whelan J., J. Lipid Res., 35, 1867-1877 (1994).
21. Schiltz J. C., Sawchenko P. E., J. Neurosci., 22, 5606-5618 (2002).
22. Quan N., He L., Lai W., Brain Res. Bull., 59, 447-452 (2003).
23. Torok K., Nemeth K., Erdo F., Aranyi P., Szekely J. I., Inflamm. Res., 44, 248-252 (1995).
24. Kolaczkowska E., Seljelid R., Plytycz B., J. Leukoc. Biol., 69, 33-42 (2001).
25. Watanabe S., Onozaki K., Yamamoto S., Okuyama H., J. Leukoc. Biol., 53, 151-156 (1993).